AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$LTRN

Lantern Pharma Inc.

Price · $LTRNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $LTRN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $LTRN in the last 30 days.

Top stories · $LTRNMore →
APR 2·The Progress IndexMed

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

RedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.

JAN 13·BioSpectrum India

Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru

US-based Lantern Pharma Inc., a company focused on AI-driven precision oncology, has announced the opening of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru, India. This initiative aims to scale up Lantern's AI platform globally, expanding its computational capacity and technical talent. The center will support both Lantern's internal pipeline and collaborations, enhancing its proprietary RADR® AI platform and accelerating the development of specialized large language models and quantitative models for drug discovery.

AUG 13·Motley Fool

Lantern Pharma Narrows Loss in Q2

Lantern Pharma ( NASDAQ:LTRN ) , a biotech focused on AI-enabled precision oncology, released its earnings for the quarter ended June 30, 2025, on August 13, 2025. Lantern Pharma reported a GAAP net loss per share of ( $0.40 ) in Q2 2025, and marking an improvement from ( $0.46 ) per share ( GAAP ...

News on $LTRN